NCT06799247View on ClinicalTrials.gov

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

PHASE3RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 6, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

September 30, 2027

Conditions
Myasthaenia Gravis
Interventions
BIOLOGICAL

Decartes-08

Autologous mRNA CAR T-cell therapy

OTHER

Placebo Drug

infusion without Decartes-08

Trial Locations (13)

10065

RECRUITING

A47, New York

14226

RECRUITING

A12, Amherst

27599

RECRUITING

A22, Chapel Hill

32751

RECRUITING

A48, Maitland

33612

RECRUITING

A10, Tampa

85718

RECRUITING

A40, Tucson

92011

RECRUITING

A13, Carlsbad

92868

RECRUITING

A14, Orange

02111

RECRUITING

A38, Boston

Unknown

RECRUITING

A24, Belgrade

RECRUITING

A31, Madrid

RECRUITING

A32, Ankara

RECRUITING

A17, Istanbul

Sponsors
All Listed Sponsors
lead

Cartesian Therapeutics

INDUSTRY